Two Brothers With Mild Congenital Erythropoietic Porphyria Due to a Novel Genotype | Genetics and Genomics | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
Observation
December 2005

Two Brothers With Mild Congenital Erythropoietic Porphyria Due to a Novel Genotype

Author Affiliations

Author Affiliations: Department of Dermatology, Henry Ford Hospital, Detroit, Mich (Drs Berry and Lim); Department of Human Genetics, Mount Sinai School of Medicine of New York University, New York (Drs Desnick, Astrin, and Shabbeer); and Dermatology Associates of Cincinnati and Cincinnati Children’s Hospital, Cincinnati, Ohio (Dr Lucky).

Arch Dermatol. 2005;141(12):1575-1579. doi:10.1001/archderm.141.12.1575
Abstract

Background  Congenital erythropoietic porphyria (CEP) is a rare autosomal recessive disease caused by the deficient activity of the heme biosynthetic enzyme, uroporphyrinogen III synthase (URO-synthase), and the accumulation of the nonphysiologic and phototoxic porphyrin I isomers. Clinical manifestations range from severe mutilation to mild erosions and blisters on sun-exposed areas. Evaluation of the URO-synthase mutation and residual enzyme activity has been correlated with the phenotypic expression of the disease.

Observations  We describe 16- and 4-year-old brothers with CEP with a mild phenotype due to a novel genotype, one allele having a promoter mutation (−76G→A) and the other having an exonic missense mutation (G225S). The father and a 4-year-old fraternal twin brother were carriers of the −76G→A mutation, whereas the mother and a 15-year-old brother were carriers of the G225S mutation. Previous in vitro expression studies demonstrated that the G225S mutation severely decreased URO-synthase activity to 1.2% of normal, whereas the promoter mutation decreased the activity to approximately 50% of wild type, accounting for the mild clinical phenotype.

Conclusion  The mild disease phenotype in these patients is a further example of the clinical heterogeneity seen in CEP and is additional proof that in vitro enzyme expression studies provide dependable genotype-phenotype correlations.

×